8-123681253-G-A
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The ENST00000419625.6(ANXA13):c.938C>T(p.Ala313Val) variant causes a missense change. The variant allele was found at a frequency of 0.000026 in 1,613,774 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.000053 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000023 ( 0 hom. )
Consequence
ANXA13
ENST00000419625.6 missense
ENST00000419625.6 missense
Scores
3
7
9
Clinical Significance
Conservation
PhyloP100: 4.82
Genes affected
ANXA13 (HGNC:536): (annexin A13) This gene encodes a member of the annexin family. Members of this calcium-dependent phospholipid-binding protein family play a role in the regulation of cellular growth and in signal transduction pathways. The specific function of this gene has not yet been determined; however, it is associated with the plasma membrane of undifferentiated, proliferating endothelial cells and differentiated villus enterocytes. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 0 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.24413937).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ANXA13 | NM_004306.4 | c.938C>T | p.Ala313Val | missense_variant | 11/11 | ENST00000419625.6 | NP_004297.2 | |
ANXA13 | NM_001003954.3 | c.1061C>T | p.Ala354Val | missense_variant | 12/12 | NP_001003954.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ANXA13 | ENST00000419625.6 | c.938C>T | p.Ala313Val | missense_variant | 11/11 | 1 | NM_004306.4 | ENSP00000390809.1 | ||
ANXA13 | ENST00000262219.10 | c.1061C>T | p.Ala354Val | missense_variant | 12/12 | 1 | ENSP00000262219.6 |
Frequencies
GnomAD3 genomes AF: 0.0000525 AC: 8AN: 152246Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
8
AN:
152246
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000677 AC: 17AN: 251172Hom.: 0 AF XY: 0.0000442 AC XY: 6AN XY: 135744
GnomAD3 exomes
AF:
AC:
17
AN:
251172
Hom.:
AF XY:
AC XY:
6
AN XY:
135744
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000233 AC: 34AN: 1461410Hom.: 0 Cov.: 34 AF XY: 0.0000179 AC XY: 13AN XY: 726996
GnomAD4 exome
AF:
AC:
34
AN:
1461410
Hom.:
Cov.:
34
AF XY:
AC XY:
13
AN XY:
726996
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000525 AC: 8AN: 152364Hom.: 0 Cov.: 33 AF XY: 0.0000403 AC XY: 3AN XY: 74514
GnomAD4 genome
AF:
AC:
8
AN:
152364
Hom.:
Cov.:
33
AF XY:
AC XY:
3
AN XY:
74514
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
11
Asia WGS
AF:
AC:
2
AN:
3478
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 26, 2024 | The c.1061C>T (p.A354V) alteration is located in exon 12 (coding exon 12) of the ANXA13 gene. This alteration results from a C to T substitution at nucleotide position 1061, causing the alanine (A) at amino acid position 354 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Uncertain
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Benign
.;T
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;D
M_CAP
Benign
T
MetaRNN
Benign
T;T
MetaSVM
Benign
T
MutationAssessor
Uncertain
.;M
MutationTaster
Benign
D;D
PrimateAI
Uncertain
T
PROVEAN
Uncertain
D;D
REVEL
Benign
Sift
Benign
T;T
Sift4G
Uncertain
T;T
Polyphen
D;D
Vest4
MutPred
0.51
.;Gain of methylation at K309 (P = 0.0496);
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at